TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05820165

Intervention type: RADIATION
Intervention: high-resolution 3D-T1
Description: Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images

Intervention type: RADIATION
Intervention: high-resolution 3D-T1
Description: Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images

Intervention type: RADIATION
Intervention: diffusion tensor imaging (DTI)
Description: Subjects undergo a DTI imaging to obtain images of white matter lesions

Intervention type: RADIATION
Intervention: diffusion tensor imaging (DTI)
Description: Subjects undergo a DTI imaging to obtain images of white matter lesions

Intervention type: RADIATION
Intervention: diffusion tensor imaging (DTI)
Description: Subjects undergo a DTI imaging to obtain images of white matter lesions

Intervention type: RADIATION
Intervention: resting-state functional magnetic resonance imaging (rs-fMRI)
Description: Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity

Intervention type: RADIATION
Intervention: resting-state functional magnetic resonance imaging (rs-fMRI)
Description: Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity

Intervention type: RADIATION
Intervention: resting-state functional magnetic resonance imaging (rs-fMRI)
Description: Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity

Intervention type: RADIATION
Intervention: arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)
Description: Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions

Intervention type: RADIATION
Intervention: arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)
Description: Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions

Intervention type: RADIATION
Intervention: arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)
Description: Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions

Intervention type: RADIATION
Intervention: susceptibility-weighted images (SWIs)
Description: Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network

Intervention type: RADIATION
Intervention: susceptibility-weighted images (SWIs)
Description: Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network

Intervention type: RADIATION
Intervention: susceptibility-weighted images (SWIs)
Description: Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
Study: NCT06020898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Description: Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
Study: NCT05486962

Intervention type: BEHAVIORAL
Intervention: Remote Patient Monitoring
Description: Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
Study: NCT05062759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: 210 mg SC injection Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection Q4W.
Study: NCT04735874

Intervention type: OTHER
Intervention: Evaluate vascular disease risk factors in children with Down Syndrome
Description: We will determine CV disease risk profiles in children with DS at our centers. We will compare these data to published national norms of children without DS. Risk factor data will include: anthropometric measures; blood pressure; history of congenital heart disease and associated surgery, sleep apnea, hypothyroidism, and cancer; fasting blood draw \[lipid panel with subfractions (NMR), insulin, glucose, and CRP\].

Intervention type: OTHER
Intervention: Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome
Description: We will perform PWV, CIMT, and CD studies in children with DS and compare these data to available data in children without DS. We will also perform multivariable analysis of the influence of combinations of CV disease risk factors on markers of early atherosclerosis in children with DS. Hypothesis: CV disease risk factors will correlate with markers of early atherosclerosis in children with DS but the associations between risk factors and markers of early atherosclerosis will differ between children with DS vs. the general population of children.
Study: NCT04757493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prucalopride 2mg
Description: Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride 2mg
Description: Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.
Study: NCT06344403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: analgesic
Description: Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: analgesic
Description: Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tender point infiltration
Description: Lidocaine mixed with diprospan injected into tender points.
Study: NCT05083689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide
Description: 31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injections of 1.25 mg of intravitreal bevacizumab with artificial tears
Description: 31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
Study: NCT06352476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Training
Description: The effect of sleep hygiene education in a pre-test quasi-experimental study.
Study: NCT06116734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grastofil®
Description: On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapelga
Description: On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection
Study: NCT05265975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-010
Description: Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral administration,QD, Days 1-21 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous injection Days 1 of each cycle, Cycles 1-6
Study: NCT05949073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-impregnated retraction cords/ less than 10 minutes
Description: lower first molar will be prepared for full coverage restoration, plain retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-impregnated retraction cords/ more than 10 minutes
Description: the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then a plain retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: impregnated gingival retraction cord - less than 10 minutes
Description: lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: impregnated gingival retraction cord - more than 10 minutes
Description: the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
Study: NCT06239740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group
Description: The acupuncture needle was placed on the scalp at a Chinese traditional acupuncture point. Subsequently, a small electrode was attached to the needle. A minor amount of electricity runs through the electrode, producing a slight vibration or soft hum during the treatment.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
Study: NCT05364892

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples (80 mL)
Description: Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Fecal samples
Description: Fecal samples at inclusion
Study: NCT06098482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Research App (MRA)
Description: The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Research App (MRA)
Description: The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.
Study: NCT05364892

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary sample (20-40 mL)
Description: Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
Study: NCT05839795

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment study
Description: Evaluation of musculoskeletal-related pain, posture, spine function, lumbar and neck regions, musculoskeletal disorder, fatigue, and quality of life
Study: NCT05220709

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bio impedance spectroscopy by means of the Body Composition Monitor (Name of the device is BCM from Fresenius Medical Care D GmbH)
Description: The Body Composition Monitor provides information about the hydration status by a bioimpedance spectroscopy measurement of the body composition from which the level of overhydration can be derived. Four electrodes are used per measurement. All subjects get electrodes attached, following the wrist-ankle approach, in a tetrapolar arrangement. Two electrodes are placed on the hand: one on the wrist, and the second on the dorsal side of the metacarpalia, close to the phalanges. The other two electrodes are placed on the foot: one on the ankle, and the second on the dorsal side of the metatarsals, close to the phalanges of the toes. Age, gender, height, weight and blood pressure are registered in the device before starting the measurement. If the quality calculated by BCM is \< 60%, the measurement will be repeated again. Measurements are taken under supervision of a trained technician or nurse.
Study: NCT06098482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC/validated delivery of the speech perception test material
Description: This involves the delivery of speech perception test material in the sound booth in a clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC/validated delivery of the speech perception test material
Description: This involves the delivery of speech perception test material in the sound booth in a clinic.
Study: NCT04573829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home visit
Description: Psychologist come once a week for the carer and three times a week for the patient
Study: NCT06268548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual diaphragmatic activation
Description: Manual diaphragm release on diaphragm
Study: NCT05646498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed sinus lift procedure
Description: The closed sinus lift is the elevation of the sinus membrane through the osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed sinus lift procedure
Description: The closed sinus lift is the elevation of the sinus membrane through the osteotomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crestal sinus lift
Description: The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crestal sinus lift
Description: The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
Study: NCT05474352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allon System
Description: Water garments (Allon system) already pre-filled with warm water will be set up before induction of anesthesia. After the induction of general anesthesia, the water garment will cover the lower and upper extremities, the lateral portion of the chest, and the entire back of the patient, which accounts for 70% of the body surface. The water garment will be opened temporarily on the upper extremities for intravenous access and arterial line placement and will be continued intraoperatively until the patient is transferred from the OR table to the stretcher
Study: NCT05001035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of assessment
Description: Immediate and after one month and after two months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of assessment
Description: Immediate and after one month and after two months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of assessment
Description: Immediate and after one month and after two months
Study: NCT05546151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986322
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986322
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986322
Description: Specified dose on specified days
Study: NCT05201118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT103A
Description: CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
Study: NCT06540534

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: In the adjuvan group (dexamethasone)group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of dexamethasone(8mg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kontrol group
Description: In the control group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of 0.9% saline.
Study: NCT06196632

Intervention type: DRUG
Intervention: Peginterferon-α; Nucleoside analogs
Description: Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

Intervention type: DRUG
Intervention: Peginterferon-α; Nucleoside analogs
Description: Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

Intervention type: DRUG
Intervention: Peginterferon-α; Nucleoside analogs
Description: Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

Intervention type: DRUG
Intervention: Peginterferon-α; Nucleoside analogs
Description: Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
Study: NCT04893265

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging Only
Description: Active Comparator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INFORMED
Description: Experimental
Study: NCT05567354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 100 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone HCl IR 40mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo powder
Study: NCT05853341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RID-TDS 13.3 mg/24 h
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon® 13.3 mg/24 h
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Study: NCT05608746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Home-based individualized training, consisting of unsupervised aerobic exercise and resistance exercise, with moderate intensity. The pt. receives an exercise manual and exercise videos online, through an APP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor exercise
Description: Patients will be assessed by a physiotherapist and instructed in a pelvic floor exercise program, accessed through the APP. Furthermore, the pt. is provided with general information about pelvic floor anatomy and muscle function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual counseling
Description: Patients will be provided with 1 video-consultation with a clinical sexologist, during the prehabilitation period. The patients will be instructed in strategies to improve postoperative communication regarding, sex, realistic expectations, erectile dysfunction and the use of aids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Patients are systematically screened for malnutrition to assess the nutritional status. Patients are given recommendations with dietary advice online, through the APP. If the patient is at nutritional risk, the patient is provided with a nutritional supplement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress management
Description: Patients are systematically screened for anxiety and depression. If patients are at risk of anxiety or depression, they are referred to a consultation with a nurse, who will provide information and strategies to handle the uncertainties they may experience.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard pre-surgical preparation and pt. information.
Description: One week preoperatively the usual regime for the presurgical preparation and information will be followed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pre-surgical preparation and pt. information.
Description: One week preoperatively the usual regime for the presurgical preparation and information will be followed.